Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+3.71M
-
Total reported value, excl. options
-
$246M
-
Value change
-
+$77.2M
-
Number of buys
-
54
-
Number of sells
-
-7
-
Price
-
$20.80
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2017
67 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2017.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 62.2M outstanding shares and own 19.04% of the company stock.
Largest 10 shareholders include FMR LLC (3.07M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.06M shares), Pharmstandard International S.A. (982K shares), FARALLON CAPITAL MANAGEMENT LLC (900K shares), BlackRock Inc. (495K shares), Vanguard Group Inc (483K shares), FIRST MANHATTAN CO (416K shares), Cormorant Asset Management, LLC (400K shares), BVF INC/IL (294K shares), and EVENTIDE ASSET MANAGEMENT, LLC (275K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.